Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae

Applied and Environmental Microbiology

Volumn 78, Issue 16, 2012, Pages 5646-5652

  Hall, Alex R ^a   De Vos, Daniel ^b   Friman, Ville Petri ^a,c   Pirnay, Jean Paul ^b   Buckling, Angus ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b QUEEN ASTRID MILITARY HOSPITAL   (Belgium)

^c UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DENSITY; BACTERIAL INFECTIONS; BACTERIAL POPULATION; IN-VITRO; LIFE SPAN; P.AERUGINOSA; PHAGE COCKTAIL; PHAGE THERAPY; PSEUDOMONAS AERUGINOSA; REDUCED GROWTH RATE; SEQUENTIAL APPLICATIONS; TIME-SCALES;

BACTERIA; POPULATION STATISTICS;

BACTERIOPHAGES;

BACTERIOPHAGE; FITNESS; GROWTH RATE; INFECTIOUS DISEASE; LARVA; MOTH; POPULATION DENSITY; TIMESCALE;

ANIMAL; ARTICLE; BIOLOGICAL THERAPY; DISEASE MODEL; GROWTH, DEVELOPMENT AND AGING; LARVA; METHODOLOGY; MICROBIOLOGY; MOTH; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; PSEUDOMONAS PHAGE; SURVIVAL; VIROLOGY;

ANIMALS; BIOLOGICAL THERAPY; DISEASE MODELS, ANIMAL; LARVA; MOTHS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; PSEUDOMONAS PHAGES; SURVIVAL ANALYSIS;

BACTERIA (MICROORGANISMS); LEPIDOPTERA; PSEUDOMONAS AERUGINOSA;

EID: 84866148808     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.00757-12     Document Type: Article

References (36)

1. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. 2011. Phage treatment of human infections. Bacteriophage. 1:66-85.
2. Alisky J, Iczkowski K, Rapoport A, Troitsky N. 1998. Bacteriophages show promise as antimicrobial agents. J. Infect. 36:5-15.
3. Andersson DI, Hughes D. 2010. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat. Rev. Microbiol. 8:260-271.
4. Brockhurst MA, Morgan AD, Fenton A, Buckling A. 2007. Experimental coevolution with bacteria and phage. The Pseudomonas fluorescens-φ2 model system. Infect. Genet. Evol. 7:547-552.
5. Brüssow H. 2005. Phage therapy: the Escherichia coli experience. Microbiology. 151:2133-2140.
6. Buckling A, Rainey PB. 2002. Antagonistic coevolution between a bacterium and a bacteriophage. Proc. R. Soc. London Ser. B Biol. Sci. 269:931-936.
7. Bull JJ, Levin BR, DeRouin T, Walker N, Bloch CA. 2002. Dynamics of success and failure in phage and antibiotic therapy in experimental infections. BMC Microbiol. 2:35. doi:10.1186/1471-2180-2-35.
8. Cairns BJ, Payne RJ. 2008. Bacteriophage therapy and the mutant selection window. Antimicrob. Agents Chemother. 52:4344-4350.
9. Callaway TR, et al. 2008. Bacteriophage isolated from feedlot cattle can reduce Escherichia coli O157:H7 populations in ruminant gastrointestinal tracts. Foodborne Pathog. Dis. 5:183-191.
10. Dennehy JJ, Turner PE. 2004. Reduced fecundity is the cost of cheating in RNA virus φ6. Proc. R. Soc. London Ser. B Biol. Sci. 271:2275-2282.
11. Hall AR, Griffiths VF, MacLean RC, Colegrave N. 2010. Mutational neighbourhood and mutation supply rate constrain adaptation in Pseu-domonas aeruginosa. Proc. R. Soc. London Ser. B Biol. Sci. 277:643-650.
12. Hall AR, MacLean RC. 2011. Epistasis buffers the fitness effects of rifam-picin-resistance mutations in Pseudomonas aeruginosa. Evolution. 65:2370-2379.
13. Harper DR, Enright MC. 2011. Bacteriophages for the treatment of Pseu- domonas aeruginosa infections. J. Appl. Microbiol. 111:1-7.
14. Harrison F, Browning LE, Vos M, Buckling A. 2006. Cooperation and virulence in acute Pseudomonas aeruginosa infections. BMC Biol. 4:21. doi:10.1186/1741-7007-4-21.
15. Housby JN, Mann NH. 2009. Phage therapy. Drug Discov. Today. 14:536-540.
16. Labrie SJ, Samson JE, Moineau S. 2010. Bacteriophage resistance mechanisms. Nat. Rev. Microbiol. 8:317-327.
17. Levin BR, Bull JJ. 2004. Population and evolutionary dynamics of phage therapy. Nat. Rev. Microbiol. 2:166-173.
18. Livermore DM. 2002. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34:634-640.
19. Lopez-Pascua LDC, Buckling A. 2008. Increasing productivity accelerates host-parasite coevolution. J. Evol. Biol. 21:853-860.
20. MacLean RC, Hall AR, Perron GG, Buckling A. 2010. The population genetics of antibiotic resistance: integrating molecular mechanisms and treatment contexts. Nat. Rev. Genet. 11:405-414.
21. Merabishvili M, et al. 2009. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 4:e4944. doi:10.1371/journal.pone.0004944.
22. Merabishvili M, et al. 2007. Digitized fluorescent RFLP analysis (fRFLP) as a universal method for comparing genomes of culturable dsDNA viruses: application to bacteriophages. Res. Microbiol. 158:572-581.
23. Merril CR, Scholl D, Adhya SL. 2003. The prospect for bacteriophage therapy in western medicine. Nat. Rev. Drug Discov. 2:489-497.
24. Morgan AD, Bonsall MB, Buckling A. 2010. Impact of bacterial mutation rate on coevolutionary dynamics between bacteria and phages. Evolution. 64:2980-2987.
25. Morgan AD, Gandon S, Buckling A. 2005. The effect of migration on local adaptation in a coevolving host-parasite system. Nature. 437:253-256.
26. O'Flynn G, Ross RP, Fitzgerald GF, Coffey A. 2004. Evaluation of a cocktail of three bacteriophages for biocontrol of Escherichia coli O157: H7. Appl. Environ. Microbiol. 70:3417-3424.
27. Payne RJ, Phil D, Jansen VA. 2000. Phage therapy: the peculiar kinetics of self-replicating pharmaceuticals. Clin. Pharmacol. Ther. 68:225-230.
28. Perron GG, Hall AR, Buckling A. 2010. Hypermutability and compensatory adaptation in antibiotic-resistant bacteria. Am. Nat. 176:303-311.
29. Pirnay JP, et al. 2011. The phage therapy paradigm: prêt-à-porter or sur-mesure? Pharm. Res. 28:934-937.
30. Pleteneva EA, et al. 2008. Study of the diversity in a group of phages of Pseudomonas aeruginosa species PB1 (Myoviridae) and their behavior in adsorption-resistant bacterial mutants. Russian J. Genet. 44:150-158.
31. Ramaswamy S, Musser JM. 1998. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tubercle Lung Dis. 79:3-29.
32. Smith HW, Huggins MB. 1982. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J. Gen. Microbiol. 128:307-318.
33. Smith HW, Huggins MB, Shaw KM. 1987. The control of experimental Escherichia coli diarrhoea in calves by means of bacteriophages. J. Gen. Microbiol. 133:1111-1126.
34. Sulakvelidze A, Alavidze Z, Morris JG, Jr. 2001. Bacteriophage therapy. Antimicrob. Agents Chemother. 45:649-659.
35. Summers AO. 2002. Generally overlooked fundamentals of bacterial genetics and ecology. Clin. Infect. Dis. 34:S85-S92.
36. Turner PE, Burch CL, Hanley KA, Chao L. 1999. Hybrid frequencies confirm limit to coinfection in the RNA bacteriophage φ6. J. Virol. 73:2420-2424.